The funding round was led by Australian private equity firms M.H. Carnegie & Co and Brandon Capital Partners. Other investors include Split Rock Partners, Ascension Ventures and Dr. Thomas Fogarty’s Emergent Medical Partners.

EBR will conduct stimulation of the left ventricle endocardially (SOLVE-CRT) study to evaluate the safety and efficacy of WiSE technology.

The data gathered from the global heart failure trial will be used to secure approval for the technology from the US Food and Drug Administration.

WiSE technology is claimed to be the only wireless and endocardial pacing system that will stimulate left ventricle of the heart.

The technology will enable cardiac pacing with a novel cardiac implant, which is about the size of a large grain of rice.

The firm has developed the patented and advanced technology to avoid the use of cardiac pacing leads, which create more complications and lead to reliability issues in cardiac rhythm disease management.

Separately, EBR has secured CE mark approval for its second-generation wireless transmitter, which is half the size of the first-generation transmitter

EBR Systems chairman and CEO Allan Will said: “We are pleased to have the support of such a solid syndicate of investors and look forward to definitively proving the clinical effectiveness of wireless pacing in SOLVE-CRT.”

Image: EBR’s WiSE technology will eliminate the need for coronary sinus leads to stimulate the left ventricle. Photo: courtesy of Business Wire.